Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)

Last updated: November 12, 2021
Sponsor: Beijing Ditan Hospital
Overall Status: Active - Recruiting

Phase

1

Condition

Carcinoma

Liver Disease

Cancer

Treatment

N/A

Clinical Study ID

NCT05088733
BJDHYZY
  • Ages 18-75
  • All Genders

Study Summary

Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Meet the criteria of hepatocellular carcinoma
  • Patients who tested positive for hepatitis B surface antigen (HBsAg) for >6 months
  • Meet the criteria of anemia
  • Ages Eligible for Study: ≤75 years old;
  • Informed consent from the patient.

Exclusion

Exclusion Criteria:

  • Patients with upper gastrointestinal bleeding within 3 months before enrollment;
  • History of blood transfusion within 3 months before enrollment;
  • Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;
  • Serious problem of heart, lung, or kidney with severe dysfunction;
  • Pregnant or child breast feeding women;
  • Mental or cognitive disorders;
  • Participating in other drug trials;
  • Who are allergic to the study drug.

Study Design

Total Participants: 120
Study Start date:
July 01, 2020
Estimated Completion Date:
June 30, 2023

Connect with a study center

  • Zhiyun Yang

    Beijing, Beijing 100015
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.